Published in Nat Clin Pract Oncol on July 01, 2007
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Br J Cancer (2016) 1.70
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open (2012) 1.50
Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci U S A (2010) 1.26
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem (2009) 1.15
Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol (2012) 1.09
Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2011) 1.07
MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int (2014) 1.07
Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Clin Pract Gastroenterol Hepatol (2009) 1.06
Residual hepatocellular carcinoma after oxaliplatin treatment has increased metastatic potential in a nude mouse model and is attenuated by Songyou Yin. BMC Cancer (2010) 1.03
Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma (2013) 1.03
Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation. Oncotarget (2015) 1.01
Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol (2008) 0.99
Hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.95
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. World J Gastroenterol (2009) 0.92
Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol (2010) 0.91
Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol (2015) 0.89
MiR-199a regulates cell proliferation and survival by targeting FZD7. PLoS One (2014) 0.89
Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol (2009) 0.89
Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol (2013) 0.89
Novel therapeutic approaches for hepatocellulcar carcinoma: fact and fiction. World J Gastroenterol (2008) 0.88
Epigenetic signatures of alcohol abuse and hepatitis infection during human hepatocarcinogenesis. Oncotarget (2014) 0.87
Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol (2014) 0.86
Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol (2009) 0.85
Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther (2013) 0.85
A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.84
Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China. Medicine (Baltimore) (2015) 0.83
Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol (2012) 0.83
Management of "very early" hepatocellular carcinoma on cirrhotic patients. World J Hepatol (2014) 0.82
Prevalence and clinical relevance of T-helper cells, Th17 and Th1, in hepatitis B virus-related hepatocellular carcinoma. PLoS One (2014) 0.81
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model. Oncotarget (2016) 0.80
Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation. PLoS One (2011) 0.80
New and old technologies for organ replacement. Curr Opin Organ Transplant (2013) 0.79
Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget (2016) 0.79
Selection criteria for liver resection in patients with hepatocellular carcinoma and chronic liver disease. World J Gastroenterol (2008) 0.78
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases. J Gastroenterol (2013) 0.78
High-resolution melting analysis reveals genetic polymorphisms in microRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer (2014) 0.78
The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model. J Exp Clin Cancer Res (2014) 0.78
Decreased expression of serum miR-424 correlates with poor prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Pathol (2015) 0.78
Integrative genomics: liver regeneration and hepatocellular carcinoma. J Cell Biochem (2012) 0.77
An accurate predictor of liver failure and death after hepatectomy: a single institution's experience with 478 consecutive cases. World J Gastroenterol (2014) 0.77
Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology (2008) 0.77
Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res (2015) 0.77
Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. Oncotarget (2015) 0.76
MicroRNA-655-3p functions as a tumor suppressor by regulating ADAM10 and β-catenin pathway in Hepatocellular Carcinoma. J Exp Clin Cancer Res (2016) 0.76
Screening and Identification of ssDNA Aptamer for Human GP73. Biomed Res Int (2015) 0.75
Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma. Exp Ther Med (2016) 0.75
TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatobiliary Surg Nutr (2014) 0.75
Clinical research on alternating hyperfraction radiotherapy for massive hepatocellular carcinoma. Oncol Lett (2015) 0.75
ITPKA expression is a novel prognostic factor in hepatocellular carcinoma. Diagn Pathol (2015) 0.75
Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus-related and non-B, non-C hepatocellular carcinoma in Xinjiang, China. Chin J Cancer Res (2015) 0.75
Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide. Orphanet J Rare Dis (2017) 0.75
Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Ther Clin Risk Manag (2015) 0.75
Hepatocellular Carcinoma: Intra-arterial Delivery of Doxorubicin-loaded Hollow Gold Nanospheres for Photothermal Ablation-Chemoembolization Therapy in Rats. Radiology (2016) 0.75
Accelerated carcinogenesis following liver resection in chronically inflamed livers: A window of opportunity for treatment. Biomed Rep (2017) 0.75
Rapidly progressing osteomyelitis of the mandible. Case Rep Dent (2013) 0.75
Salvage Liver Transplantation Leads to Poorer Outcome in Hepatocellular Carcinoma Compared with Primary Liver Transplantation. Sci Rep (2017) 0.75
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interfaces (2016) 0.75
Optimal treatment for hepatocellular carcinoma in the cirrhotic liver. Ann R Coll Surg Engl (2009) 0.75
Institutional guidelines and ongoing studies in management of liver tumours: the experience of the European Institute of Oncology. Ecancermedicalscience (2008) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology (2013) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol (2008) 2.22
MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology (2011) 1.77
Hepatic resection for primary hepatolithiasis: a single-center Western experience. J Am Coll Surg (2012) 1.70
Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg (2015) 1.53
Intrahepatic cholangiocarcinoma: new insights in pathology. Semin Liver Dis (2011) 1.46
De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45
Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg (2004) 1.36
Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. Ann Surg (2015) 1.17
Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant (2004) 1.17
Feasibility and preliminary accuracy of high-resolution imaging of the liver and pancreas using FNA compatible microendoscopy (with video). Gastrointest Endosc (2012) 1.09
Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07
Hilar cholangiocarcinoma involving the portal vein bifurcation: long-term results after resection. J Hepatobiliary Pancreat Surg (2002) 1.03
Postchemotherapy resection of a primary mature malignant retroperitoneal teratoma in an adult: report of a case. Surg Today (2005) 1.02
Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl (2009) 1.02
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience. Am J Surg (2008) 1.02
Differences in surgical outcomes between hepatitis B- and hepatitis C-related hepatocellular carcinoma: a retrospective analysis of a single North American center. Ann Surg (2014) 0.99
How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol (2005) 0.97
Liver transplantation for neuroendocrine tumors. J Gastrointest Surg (2004) 0.93
Cholangiolocellular carcinoma: an innocent-looking malignant liver tumor mimicking ductular reaction. Semin Liver Dis (2011) 0.91
Recurrence of hepatocellular carcinoma after liver transplantation: is immunosuppression a factor? Liver Transpl (2005) 0.90
Multifocal hepatocellular carcinoma and precancerous lesions in a patient with autoimmune hepatitis-related cirrhosis. Semin Liver Dis (2008) 0.88
Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review. Pediatr Transplant (2015) 0.88
Resection of hepatocellular carcinoma without cirrhosis. Ann Surg (2012) 0.87
Retracted Liver functional reserve estimation: state of the art and relevance to local treatments. Oncology (2010) 0.86
Does anatomic versus nonanatomic resection affect recurrence and survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol (2008) 0.86
Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging (2011) 0.86
Giant hemangioma of the adrenal. Isr Med Assoc J (2004) 0.85
Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB (Oxford) (2013) 0.84
Revised staging classification improves outcome prediction for small intestinal neuroendocrine tumors. J Clin Oncol (2013) 0.84
Carcinoma ex microcystic adenoma of the pancreas: a report of a novel form of malignancy in serous neoplasms. Am J Surg Pathol (2012) 0.83
Marked Differences in acute cellular rejection rates between living-donor and deceased-donor liver transplant recipients. Transplantation (2005) 0.83
Liver functional reserve estimation: state of the art and relevance for local treatments: the Western perspective. J Hepatobiliary Pancreat Sci (2009) 0.83
Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl (2006) 0.82
Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? Breast (2002) 0.82
Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl (2005) 0.82
The role of fibrin sealants in hepatic surgery. Surg Technol Int (2007) 0.81
Diaphragmatic hernia after hepatic resection: case series at a single Western institution. J Gastrointest Surg (2012) 0.81
The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer (2014) 0.81
Subclinical peritonitis due to perforated sigmoid diverticulitis 14 years after heart-lung transplantation. World J Gastroenterol (2008) 0.81
Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology (2015) 0.79
Clinical research in hepatocellular carcinoma: study design and endpoints. J Hepatol (2009) 0.79
Multiple endocrine neoplasia type 1 associated with a new mutation in the menin gene and a midgut neuroendocrine tumor. Pancreas (2014) 0.79
FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med (2007) 0.79
Alternations of 14-3-3 θ and β protein levels in brain during experimental sepsis. J Neurosci Res (2011) 0.78
Combined adult-to-adult living donor right lobe liver transplantation and pancreatoduodenectomy for distal bile duct adenocarcinoma in a patient with primary sclerosing cholangitis. J Am Coll Surg (2003) 0.78
Surgical resection for advanced gallbladder carcinoma. The Mount Sinai experience. Hepatogastroenterology (2011) 0.78
Multiple inflammatory and serum amyloid A positive telangiectatic hepatic adenomas with glycogenated nuclei arising in a background of nonalcoholic steatohepatitis. Semin Liver Dis (2008) 0.77
Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. HPB (Oxford) (2012) 0.77
Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol (2013) 0.77
Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. AJR Am J Roentgenol (2013) 0.77
The continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer offers a survival benefit. Hepatogastroenterology (2012) 0.77
Administration of Human Protein-C concentrate prevents apoptotic brain cell death after experimental sepsis. Brain Res (2009) 0.77
A two-step right hepatic lobectomy with portal vein ligation for large hepatocellular carcinoma: rapid induction of left-lobe regeneration and clinicopathologic correlation. Semin Liver Dis (2013) 0.76
Functional abdominal complaints occurred frequently in living liver donors after donation. Scand J Gastroenterol (2010) 0.76
Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int J Surg Oncol (2012) 0.76
Expansion of criteria for transplanting patients with hepatocellular carcinoma. Liver Transpl (2008) 0.75
Reply:. Hepatology (2013) 0.75
Recurrent giant hemangiomas of liver: Report of two rare cases with literature review. World J Gastrointest Surg (2012) 0.75
Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases. Pancreas (2016) 0.75
Metastatic colon carcinoma to the gallbladder and common hepatic duct. Am Surg (2011) 0.75
The prognostic role of carotid plaque ultrasonography in cardiac damage after carotid endarterectomy: carotid plaque and cardiac risk. Minerva Cardioangiol (2015) 0.75
Evaluation of apoptosis in nasal and buccal cells of septic patients. In Vivo (2007) 0.75
Metzenbaum-assisted liver resection: a safe and effective liver resection technique. Dig Surg (2014) 0.75
Calcified telangiectatic hyperplastic nodule associated with vascular malformation in a child: a case report. Fetal Pediatr Pathol (2014) 0.75
A 48-year-old obese man with a 3 cm liver lesion and a history of hemochromatosis and lymphoma. Semin Liver Dis (2004) 0.75
Renal artery thrombosis following secondary cytoreduction in a patient with ovarian cancer. Gynecol Oncol (2007) 0.75